G-BA finds no added benefit for the second early-Alzheimer's drug either

The Federal Joint Committee (G-BA) has found no added benefit over the current standard of care for the second new drug to treat early-stage Alzheimer's disease either. The decision is based on the clinical study data submitted by the manufacturer. Like lecanemab, which was assessed recently, donanemab targets one of the suspected causes of the disease: protein deposits in the brain. The drug is approved for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease and has been available in Germany since November 2025. Existing treatment approaches for these two patient groups, both pharmacological and non-pharmacological, focus on easing symptoms. The G-BA decision now forms the basis for the price negotiations between the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) and the manufacturer. The decision does not impose any further restrictions on prescribing donanemab.